Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals CRISPR Collaboration by Year
CRISPR Collaboration — Cost of sales / collaboration profit-sharing ($M) ($M)
Vertex Pharmaceuticals CRISPR Collaboration: $147M in FY2025, up 99.7% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K Note (Collaborative Arrangements — CRISPR Therapeutics).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | CRISPR Collaboration — Cost of sales / collaboration profit-sharing ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 147 | +99.7% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 73.5 | – | Form 10-K (filed 2026-02-13) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals CRISPR Collaboration ($M), annual FY2024–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/crispr-cogs
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.